Overall, Granzyme B delivered directly to tumor cells or tumor neovasculature appears to be a promising and exciting opportunity in the field of targeted therapy, with significant therapeutic potential in primary and metastatic disease. The gene discussed is GZMB; the disease is metastatic neoplasm.